Dysphagia, unspecified. R13.10 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
If the dysphagia is due to a prior stroke, then code 438.82, Dysphagia as late effect of cerebrovascular disease, is assigned and sequenced first followed by a code for the specific type of dysphagia (787.20 to 787.29). Dysphagia documented as functional, hysterical, or nervous is classified to code 300.11, Conversion disorder.
Treatment for dysphagia mainly depends on the type or the underlying cause. For oropharyngeal dysphagia, a speech therapist may teach a patient exercises to coordinate the swallowing muscles or teach swallowing techniques.
Oral phase dysphagia (787.21) refers to a problem with moving food from the mouth to the oropharynx. Oropharyngeal phase dysphagia (787.22) refers to problems with moving food from the oropharynx into the esophagus.
R13. 11, Dysphagia, oral phase.
14.
1 for Encounter for antineoplastic chemotherapy and immunotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
R13.19Coding for Dysphagia in ICD-10-CM R13. 19, Other dysphagia, which includes cervical dysphagia and neurogenic dysphagia.
Dysphagia, pharyngoesophageal phase R13. 14 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM R13. 14 became effective on October 1, 2021.
92526The CPT defines code 92526 as: “treatment of swallowing dysfunction and/or oral function for feeding.” Enrolled speech and language pathologists (SLPs), physicians, and qualified non-physician practitioners (NPP) will be allowed to bill using this code for dates of service on or after January 1, 2016, when the service ...
Code 96413 (chemotherapy administration, intravenous infusion technique; up to one hour, single or initial substance/drug) would be used to report the first 90 minutes of the infusion.
ICD-10-CM Code for Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter T45. 1X5A.
ICD-10 Code for Other long term (current) drug therapy- Z79. 899- Codify by AAPC.
A screening colonoscopy should be reported with the following International Classification of Diseases, 10th edition (ICD-10) codes: Z12. 11: Encounter for screening for malignant neoplasm of the colon. Z80. 0: Family history of malignant neoplasm of digestive organs.
Oropharyngeal or transfer dysphagia is characterized by difficulty initiating a swallow. Swallowing may be accompanied by nasopharyngeal regurgitation, aspiration, and a sensation of residual food remaining in the pharynx. ●
Dysphagia is the medical term for swallowing difficulties. Some people with dysphagia have problems swallowing certain foods or liquids, while others can't swallow at all. Other signs of dysphagia include: coughing or choking when eating or drinking. bringing food back up, sometimes through the nose.
In most cases the manifestation codes will have in the code title, "in diseases classified elsewhere.". Codes with this title are a component of the etiology/manifestation convention. The code title indicates that it is a manifestation code.
The 2022 edition of ICD-10-CM I69.391 became effective on October 1, 2021.
When a primary malignancy has been previously excised or eradicated from its site and there is no further treatment directed to that site and there is no evidence of any existing primary malignancy at that site, a code from category Z85, Personal history of malignant neoplasm, should be used to indicate the former site of the malignancy. Any mention of extension, invasion, or metastasis to another site is coded as a secondary malignant neoplasm to that site. The secondary site may be the principal or first-listed with the Z85 code used as a secondary code.
Chapter 2 of the ICD-10-CM contains the codes for most benign and all malignant neoplasms. Certain benign neoplasms , such as prostatic adenomas, may be found in the specific body system chapters. To properly code a neoplasm, it is necessary to determine from the record if the neoplasm is benign, in-situ, malignant, or of uncertain histologic behavior. If malignant, any secondary ( metastatic) sites should also be determined.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion '), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous such as tumors in different quadrants of the same breast, codes for each site should be assigned.
The neoplasm table in the Alphabetic Index should be referenced first. However, if the histological term is documented, that term should be referenced first, rather than going immediately to the Neoplasm Table, in order to determine which column in the Neoplasm Table is appropriate. Alphabetic Index to review the entries under this term and the instructional note to “see also neoplasm, by site, benign.” The table provides the proper code based on the type of neoplasm and the site. It is important to select the proper column in the table that corresponds to the type of neoplasm. The Tabular List should then be referenced to verify that the correct code has been selected from the table and that a more specific site code does not exist.
When a pregnant woman has a malignant neoplasm, a code from subcategory O9A.1 -, malignant neoplasm complicating pregnancy, childbirth, and the puerperium, should be sequenced first, followed by the appropriate code from Chapter 2 to indicate the type of neoplasm. Encounter for complication associated with a neoplasm.
When the reason for admission/encounter is to determine the extent of the malignancy, or for a procedure such as paracentesis or thoracentesis, the primary malignancy or appropriate metastatic site is designated as the principal or first-listed diagnosis, even though chemotherapy or radiotherapy is administered.
When a patient is admitted because of a primary neoplasm with metastasis and treatment is directed toward the secondary site only , the secondary neoplasm is designated as the principal diagnosis even though the primary malignancy is still present .
Dysphagia documented as functional, hysterical, nervous, or psychogenic is classified to code F45.8, Other somatoform disorders.
Psychogenic dysphagia is assigned to code 306.4, Gastrointestinal malfunction arising from mental factors. Since dysphagia is a symptom, it will not be sequenced as the principal diagnosis if the underlying cause has been documented by the physician. However, the appropriate code for dysphagia may be coded and sequenced as a secondary diagnosis ...
Oropharyngeal phase dysphagia (787.22) refers to problems with moving food from the oropharynx into the esophagus. Pharyngeal phase dysphagia (787.23) results from a weakness or lack of coordination of the pharyngeal muscles; aspiration is most likely to occur in this phase. Pharyngoesophageal phase dysphagia (787.24) results from passing food into the esophagus.
Treatment for esophageal dysphagia may include esophageal dilation, surgery to remove esophageal tumor or diverticulum, or medication. Severe dysphagia may require the insertion of a feeding tube (96.6) or a percutaneous endoscopic gastrostomy tube (43.11).
Dysphagia can lead to the following complications: • malnutrition (categories 260 to 263) ; • dehydration (276.51); and. • aspiration pneumonia (507.0). Diagnosis. To diagnose the underlying cause of the dysphagia, a physician may perform any of the following tests: • barium swallow or modified barium swallow;
In other words, a symptom code should not be sequenced as the principal diagnosis when a related definitive diagnosis has been established. Since dysphagia is a symptom, it will not be sequenced as the principal diagnosis if the underlying cause has been documented by the physician. — Audrey Howard.
Dysphagia alone may not be of concern, but it may be indicative of a more serious condition requiring treatment if it persists or is severe. In addition, the condition may make it difficult for a patient to consume enough calories or fluids, which can lead to additional medical problems.